Malignant solid neoplasm Trials in Philadelphia, United States
Conditions / Malignant solid neoplasm / Philadelphia, United States
Malignant solid neoplasm is a medical condition with active clinical research programs worldwide.
32 total trials for this combination
Showing top 10 of 32 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT02402244 | Project: Every Child for Younger Patients With Cancer | RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT04387656 | NCI COVID-19 in Cancer Patients, NCCAPS Study | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT03816345 | Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO | RECRUITING | — |
| NCT03213652 | Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04387656 | NCI COVID-19 in Cancer Patients, NCCAPS Study | ACTIVE_NOT_RECRUITING | — |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | ACTIVE_NOT_RECRUITING | — |
| NCT05103358 | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT04284774 | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial | ACTIVE_NOT_RECRUITING | PHASE2 |